Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28048128 | 0.78 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL15547729 | 0.78 | SYK (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL19668758 | 0.76 | CHRNB2 (0.46) | CHRNB2CHRNA4 | |
| SCHEMBL26923027 | 0.75 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL188568 | 0.75 | CHRNB2 (0.49) | CHRNB2CHRNA4 | |
| SCHEMBL17841473 | 0.73 | CHRNB2 (0.46) | CHRNB2CHRNA4 | |
| SCHEMBL9227008 | 0.73 | CA12 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL17841557 | 0.72 | CHRNB2 (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL6253280 | 0.72 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL219260 | 0.72 | CYP11B1 (0.43) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183232-B1 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2183232-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | Amgen, Inc (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054405-A1 | PI3 kinase modulators and methods of use | PIK3CA, PIK3C2A, PIK3C2B | CHRNB2 3960/4885CHRNA4 3513/4885 |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | CHRNB2 55/4885CHRNA4 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.